{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/paronychia-acute/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"0ba4b7a5-9a25-5970-b668-a9c7c4fb38af","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field b464fe93-78fe-4367-ad1c-d5a64e87ec56 --><h2>Clarithromycin</h2><!-- end field b464fe93-78fe-4367-ad1c-d5a64e87ec56 -->","summary":"","htmlStringContent":"<!-- begin item 56b1d9cc-c80c-494e-9a2b-df2865bcef0f --><!-- end item 56b1d9cc-c80c-494e-9a2b-df2865bcef0f -->","topic":{"id":"b2bb7fc0-a6db-5872-b76f-83f50e0814ee","topicId":"6c8ca646-4291-4610-b32e-02c43d2c8af9","topicName":"Paronychia - acute","slug":"paronychia-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"9d232456-a0db-59c3-81d2-6066b705f267","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e855a6e8-ed6f-50da-8601-bb658a2c2142","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b7baf273-3ab9-5b99-91b1-7ff165d7b93e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"118743c0-8ede-55bf-b84a-3f9b8fcebdd8","slug":"changes","fullItemName":"Changes"},{"id":"4ba6812b-5e78-5829-a1ca-8f8a57fe62b4","slug":"update","fullItemName":"Update"}]},{"id":"d477c411-32be-55fe-a86e-08290f4d2b8e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c33920b-b3ac-508f-b75a-1eff779e03a1","slug":"goals","fullItemName":"Goals"},{"id":"c4185e18-cda2-5c32-93a0-5c296bd5c060","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f88d0725-e6fd-5377-81c4-23ab93a7caf9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4f840bc1-0fc7-584f-873e-932c373ceada","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1532db75-44de-553a-9f1e-252b405093a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"36684520-6e5e-55c7-9b20-a4036334ed13","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a51d8911-5c44-5fbe-891f-7a1ce243e2d0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3b0bcedc-02f6-597c-91c1-68ad812ee098","slug":"definition","fullItemName":"Definition"},{"id":"dbf72d8a-9d7c-5237-9ec4-41564c1723a2","slug":"causes","fullItemName":"Causes"},{"id":"27706fc3-d0b2-517c-a4ca-f9c337526f6e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"693a21f1-8661-5aa0-a4ad-4fd293690c1f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7b667a2-77ed-58ce-85e1-28053b3cbac6","slug":"complications","fullItemName":"Complications"},{"id":"69b0affa-ba11-50c0-b7eb-4164215fff81","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"402635e2-8b5b-510b-8911-de663be26627","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2b9d442-db59-5ce2-8001-f79b47a0d07b","slug":"clinical-presentation","fullItemName":"Clinical presentation"},{"id":"5fefa9cc-3cd1-5fe6-97c9-b95e84cf7790","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d056845a-158d-5904-925f-c1f2590f7c8c","fullItemName":"Management","slug":"management","subChapters":[{"id":"2f065baa-02b7-57a9-a6f9-036079cc78af","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b8188aa3-5a20-53fc-9ac5-f1500bcb20ee","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2fead58-dca1-5103-8ad8-61ea6110cd3e","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0ba4b7a5-9a25-5970-b668-a9c7c4fb38af","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"17d25ace-76d2-5ab6-ac1d-8a1238ea8e09","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"6e2d0756-59aa-5521-b157-730945914705","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f5ecaf87-1d35-5c33-8736-46baa81bda4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9235cf50-84ce-54e7-b840-58aa133fc328","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"592eaa54-938e-528f-ac4e-1f2d1e7bf7b7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"37214d7d-d933-54be-90ef-dc6fabcc7943","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"599ff9f8-a29d-5b76-9429-6e0788baf48f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a58d49de-b64c-5e6e-8c5b-5c60f36f832c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2bc165bd-1fb7-56b2-8b43-476ce2b9c4a2","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b8188aa3-5a20-53fc-9ac5-f1500bcb20ee","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c41f3724-3a72-5e2a-a124-49eb6df66c7b","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 67b49bf1-f01c-45d7-8581-d468a3266780 --><h3>Dose</h3><!-- end field 67b49bf1-f01c-45d7-8581-d468a3266780 -->","summary":"","htmlStringContent":"<!-- begin item edcb573a-4d12-4f22-ab35-2b9068d1832e --><!-- begin field 07f011a5-9c17-4099-9b10-be887ca97975 --><ul><li><strong>Adults and children 12 years of age and older</strong> — 250 mg to 500 mg (in severe infection), twice daily for 7 days.</li><li><strong>Children 1 month to 11 years of age</strong><ul><li>Body weight less than 8 kg — 7.5 mg per kg twice daily.</li><li>Body weight 8–11 kg — 62.5 mg twice daily.</li><li>Body weight 12–19 kg — 125 mg twice daily.</li><li>Body weight 20–29 kg — 187.5 mg twice daily.</li><li>Body weight 30–40 kg — 250 mg twice daily.<ul><li>Oral clarithromycin is available as 250 mg and 500 mg tablets, 125 mg per 5 mL and 250 mg per 5 mL paediatric suspension, and granules containing 250 mg of clarithromycin per sachet.</li><li>Clarithromycin tablets are not licensed for use in children under 12 years of age.</li><li>Clarithromycin oral suspension is not licensed for use in infants under 6 months or age.</li></ul></li></ul></li><li>The recommendations on length of antibiotics course are extrapolated from an antibiotics guideline produced by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">PHE, 2017</a>].<ul><li>The PHE did not consider the treatment of acute paronychia but for other bacterial skin infections, such as impetigo and cellulitis, they recommend a duration of 7 days for empirical oral antibiotic treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">PHE, 2017</a>].</li></ul></li><li>CKS found no randomized controlled trials that studied the effectiveness of antibiotic treatment (or the length of antibiotic course needed) for the treatment of acute paronychia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>] </p><!-- end field 07f011a5-9c17-4099-9b10-be887ca97975 --><!-- end item edcb573a-4d12-4f22-ab35-2b9068d1832e -->","subChapters":[]},{"id":"cd3f7c4e-9e37-51f8-b662-9459dfdddfc0","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 264eb5b5-5de0-46d6-addf-a76e00c161c7 --><h3>Adverse effects</h3><!-- end field 264eb5b5-5de0-46d6-addf-a76e00c161c7 -->","summary":"","htmlStringContent":"<!-- begin item a1dfc767-ba83-44e8-8603-a76e00c15fa7 --><!-- begin field e89a13f8-1438-4bdb-bbb0-a76e00c161c7 --><ul><li><strong>Although generally well tolerated, the most common adverse effects of clarithromycin are gastrointestinal symptoms</strong> such as nausea, vomiting, and diarrhoea.</li><li><strong>Other adverse effects include:</strong><ul><li>Cholestatic jaundice.</li><li>Hepatotoxicity.</li><li>Rash.</li><li>Antibiotic-associated colitis</li><li>Arrhythmias.</li><li>Pancreatitis.</li><li>QT interval prolongation.</li><li>Stevens-Johnson syndrome and toxic epidermal necrolysis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>]</p><!-- end field e89a13f8-1438-4bdb-bbb0-a76e00c161c7 --><!-- end item a1dfc767-ba83-44e8-8603-a76e00c15fa7 -->","subChapters":[]},{"id":"f554c224-392c-5da1-880c-29da862e5d81","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8a369681-3dfe-447b-b63b-a76e00c175eb --><h3>Contraindications and cautions</h3><!-- end field 8a369681-3dfe-447b-b63b-a76e00c175eb -->","summary":"","htmlStringContent":"<!-- begin item 4e16dc21-0056-41fc-a6db-a76e00c17409 --><!-- begin field aced8b1a-f4dd-4b06-a7e7-a76e00c175eb --><ul><li><strong>Do not prescribe clarithromycin to people with:</strong><ul><li>A history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointe arrhythmias.</li><li>Hypokalaemia.</li><li>Severe hepatic failure in combination with renal impairment.</li><li>Concomitant use of certain medications (see <a class=\"topic-reference internal-reference\" href=\"/topics/paronychia-acute/prescribing-information/clarithromycin/#drug-interactions\">Drug interactions</a>).</li><li>Hypersensitivity to macrolide drugs.</li></ul></li></ul><ul><li><strong>Prescribe clarithromycin with caution in people with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, conduction disturances or clinically relevant bradycardia — increased risk of QT prolongation.</li><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with clarithromycin.</li><li>Moderate to severe renal impairment — use half the dose in severe renal impairment (eGFR less than 30mL/min). Avoid Klaricid XL<sup>®</sup>(clarithromycin 500 mg prolonged release once daily tablets) in people with eGFR less than 30 mL/min.</li><li>Conditions which predispose to QT interval prolongation, such as electrolyte disturbances and people taking drugs that prolong the QT interval (see Drug interactions) — macrolides can also prolong the QT interval, increasing the risk of Torsades de pointes arrhythmias.</li><li>Myasthenia gravis — macrolide antibiotics may aggravate myasthenia gravis.</li><li>Pregnancy — avoid use in pregnancy, particularly in the first trimester, unless the risk is outweighed by the potential benefit.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>]</p><!-- end field aced8b1a-f4dd-4b06-a7e7-a76e00c175eb --><!-- end item 4e16dc21-0056-41fc-a6db-a76e00c17409 -->","subChapters":[]},{"id":"c85f894c-76b7-5a14-ba6f-52a9e169f0a1","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7eff54f7-d5ef-4c7f-a757-a76e00c18599 --><h3>Drug interactions</h3><!-- end field 7eff54f7-d5ef-4c7f-a757-a76e00c18599 -->","summary":"","htmlStringContent":"<!-- begin item df4ba50a-dc20-447d-b0de-a76e00c1837e --><!-- begin field 63702224-12f9-4c25-af06-a76e00c18599 --><p><strong>Multiple interactions exist between clarithromycin and other drugs.</strong> The following is not an exhaustive list.</p><p><strong>Drug interactions with clarithromycin include:</strong></p><ul><li><strong>Antidiabetic drugs and insulin </strong>— the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylurias and/or insulin) can result in significant hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly and adjust the antidiabetic drug (and/or insulin) dose accordingly.</li></ul></li><li><strong>Calcium channel blockers (CCBs) </strong>— due to an increased risk of toxicity and adverse effects such as hypotension and QT prolongation, caution is advised with the concurrent use of macrolides and CCBs (such as verapamil, felodipine, nifedipine, amlodipine, and diltiazem). Doses of CCBs (particularly verapamil and felodipine) may need to be reduced.</li><li><strong>Carbamazepine </strong>— it is recommended to reduce the dose of carbamazepine by 30-50% for the duration of treatment with clarithromycin and to monitor carbamazepine levels within 3–5 days of starting treatment. Carbamazepine toxicity may present as dizziness, diplopia, ataxia and confusion.</li><li><strong>Colchicine</strong> — concomitant use of clarithromycin and colchicine is contraindicated. Deaths associated with colchicine toxicity have been reported in patients taking a combination of these medications.</li><li><strong>Drugs that prolong the QT interval </strong>— if possible, avoid giving clarithromycin to a person who is already taking a drug that can potentially prolong the QT interval, such as:<ul><li>Antiarrhythmics (such as amiodarone).</li><li>Antipsychotics (such as amisulpride and haloperidol).</li><li>Tricyclic antidepressants (such as clomipramine).</li><li>Note that concomitant administration of clarithromycin and any of the following drugs is contraindicated:<ul><li>Astemizole.</li><li>Pimozine.</li><li>Cisapride.</li><li>Terfenadine.</li></ul></li></ul></li><li><strong>Ergotamine</strong> <strong>or didydroergotamine </strong>— avoid concomitant use as clarithromycin may increase plasma concentration of ergotamine, resulting in toxicity.</li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not </em>required during or after courses of clarithromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea.</li></ul></li><li><strong>Ranolazine</strong> — avoid concomitant use as clarithromycin may increase plasma concentration of ranolazine.</li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if clarithromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — do not prescribe clarithromycin to a person taking simvastatin, as simvastatin is extensively metabolised by CYP3A4. </li><li>For atorvastatin — avoid concurrent use with clarithromycin, as atorvastatin is moderately metabolised by CYP3A4. If concurrent use cannot be avoided, consider temporarily stopping atorvastatin. Do not exceed a dose of atorvastatin 20mg, and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. However, caution is advised for patients taking pravastatin. Fluvastatin is not dependent on CYP3A metabolism; therefore, interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Ticagrelor </strong>— avoid concomitant use as clarithromycin may increase the plasma concentration of ticagrelor.</li><li><strong>Triazolobenzodiazepines</strong> — caution is recommended for the concomitant use of clarithomycin and triazolobenzodiazepines such as triazolam and midazolam. Clarithromycin inhibits metabolism of midazolam which may lead to increased sedation.</li><li><strong>Warfarin </strong>— monitor the international normalized ratio (INR) within 3 days of starting clarithromycin when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. There are reports of increased INR and prothrombin times. Clarithromycin may enhance the effect of warfarin; this is an established but unpredictable interaction.</li><li><strong>Zopiclone</strong> — caution is recommended for the concurrent use of zopiclone and erythromycin as erythromycin has been reported to decrease the clearance of zopicline leading to an increased effect. Clarithromycin would be expected to interact similarly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">CSM, 2004b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">FSRH, 2017</a>]</p><!-- end field 63702224-12f9-4c25-af06-a76e00c18599 --><!-- end item df4ba50a-dc20-447d-b0de-a76e00c1837e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}